W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY
|
Back to Search Results |
|
Catalog Number PAJR071002E |
Device Problem
Separation Failure (2547)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 09/06/2022 |
Event Type
malfunction
|
Event Description
|
According to the information gore received, while the device was in the lesion, the physician tried to deploy the device by pulling the deployment thread but it could not be done, only the tip a little.Reportedly, the thread could not equally be removed.Therefore, the physician removed the device and instead used another device which was successfully implanted.The lesion was in the left subclavia and the device was used to try to cover thrombosed area (parietal thrombus).The physician believes that the device contributed to the event and that a defect in the device prevented it from being deployed.Guidewire advanta 0,18, shift 7 fr was used as a concomitant device.
|
|
Manufacturer Narrative
|
No patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal casenumber.Heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.The physician has been contacted multiple times to provide additional information regarding the reported adverse events and the event description has already been appropriately updated.A review of manufacturing records verified that the lot involved in this complaint met all pre-release specifications.The device was evaluated and here is the report: the engineering evaluation report details observations made directly on the returned device in addition to device photos captured during evaluation.No damage to the device was noted during the evaluation, and deployment was able to continue with the knob.Therefore, engineering evaluation of the device could not confirm the reported failure mode.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
Manufacturer Narrative
|
H6: corrected imdrf codes.
|
|
Search Alerts/Recalls
|
|
|